🇺🇸 FDA
Pipeline program

Fruquintinib

2021-013-CH11 IIT-CR

Phase 2 small_molecule active

Quick answer

Fruquintinib for Rectal Cancer is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Rectal Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials